Sanofi (NASDAQ:SNY) Stock Rating Lowered by Wall Street Zen

Sanofi (NASDAQ:SNY) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other brokerages have also recently commented on SNY. Royal Bank Of Canada initiated coverage on Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a report on Wednesday, July 8th. Finally, Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Price Performance

Shares of SNY opened at $39.92 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a twelve month low of $39.50 and a twelve month high of $52.68. The stock has a market capitalization of $96.78 billion, a P/E ratio of 20.90, a P/E/G ratio of 1.20 and a beta of 0.33. The company has a 50 day moving average of $43.41 and a 200-day moving average of $44.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business had revenue of $13.36 billion during the quarter. During the same quarter in the previous year, the company posted $3.24 EPS. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, equities research analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SNY. Physician Wealth Advisors Inc. raised its position in shares of Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares in the last quarter. Western Wealth Management LLC bought a new stake in shares of Sanofi in the first quarter valued at approximately $29,000. Leonteq Securities AG grew its position in Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares in the last quarter. Fairway Wealth LLC acquired a new stake in Sanofi during the first quarter worth approximately $32,000. Finally, Purpose Unlimited Inc. bought a new position in Sanofi during the 4th quarter worth $36,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Key Headlines Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi and Regeneron added four next-generation antibodies to their alliance, including the clinical-stage IL-13 antibody REGN20423, an IL-4xIL-13 bispecific antibody, and two preclinical candidates. The products are designed to offer longer dosing intervals and could broaden the companies’ immunology franchise beyond Dupixent. Sanofi and Regeneron expand global alliance press release
• Positive Sentiment: Regeneron will receive a $1 billion upfront payment, with as much as $7 billion in additional milestone payments, making the potential deal value up to $8 billion. Sanofi will gain access to assets that could support long-term revenue growth and help replenish its specialty-care pipeline. Sanofi Regeneron expand immunology alliance
• Neutral Sentiment: The companies will split development and commercialization costs equally and share future profits. This limits Sanofi’s financial burden compared with a wholly owned program, but the milestone payments are contingent on development and commercial success rather than guaranteed. Sanofi Regeneron alliance deal
• Negative Sentiment: The $1 billion upfront payment will pressure near-term cash flow, while the newly added antibodies remain at different stages of development. Clinical, regulatory and commercial setbacks could prevent Sanofi from realizing the agreement’s headline value. Sanofi Regeneron alliance worth up to $8 billion

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.